Members Members Residents Job Board
Join Today Renew Your Membership Make A Donation
2006 Abstracts: Is total pancreatectomy (TP) safe and reasonable?
Back to 2006 Program and Abstracts
Is total pancreatectomy (TP) safe and reasonable?
Olivier Corcos1, Alain Sauvanet2, Anne Couvelard3, Olivier Farges2, Vinciane Rebours1, Pascal Hammel1, Philippe Levy1, Jacques Belghiti2, Philippe Ruszniewski1; 1service de gastroenterologie, hopital Beaujon, Clichy, France; 2service de chirurgie digestive, hopital Beaujon, Clichy, France; 3service d'anatomopathologie, hopital Beaujon, Clichy, France

Aim of the study: TP may be proposed for patients (pts) with diffuse intraductal papillary mucinous tumors of the pancreas (IPMT) or multiples endocrine tumors (mostly associated with MEN-1). Decisions pertaining to TP can be elective when abnormalities are diffuse (e.g., diffuse IPMT) or during surgery where resection margins are involved requiring further resection. Disease-relapse following partial pancreatectomy may also require surgical totalisation. Little data related to survival and morbidity is available. Patients and methods: From 1995 to 2005, 23 patients undergoing TP were retrospectively evaluated. Mean age at TP was 56 [27-76] Years. Indications for TP were: a) non-invasive diffuse IPMT (n=9) or invasive cancer (n=7), multiples endocrine tumors (n=5, 4 with MEN-1), ductal adenocarcinoma (n=1), and relapse of endocrine tumor (n=1); b) totalisation of pancreatectomy was performed in 6 pts for either relapse or incomplete resection performed a median of 2 [0-7] years before. The diagnosis was made preoperatively prior to TP in all patients except 2 (the latter included a case of SLE-related pancreatitis and multicystic chronic fibrosing pancreatitis mimicking IMPT, respectively). Morbidity related to TP and survivals were estimated. Results: Post-operative death was nil. After a median follow-up of 1.4 [0.2-12] years, 16 patients are still alive (5-year actuarial survival=70%). Seven deaths occured form relapse of adenocarcinoma (n=5), late anastomotic ulcer bleeding (n=1) and hypoglycemia (n=1). A reversible hypoglycemic coma and a gastrojejunal anastomotic ulcer were observed in 3 (15%) and 5 (20%) patients, respectively. Among the 8 patients with invasive adenocarcinoma, 5 relapsed at a median of 9 [3-19] months. Among the 8 patients not suspected of having malignant IPMT prior to surgery, 3 were found to have invasive cancer after TP. No patient with endocrine tumors died. Conclusions: After TP: 1) post operative mortality is minimal; 2) mortality due to endocrine insuffisency is 4%; 3) anastomotic ulcers are more frequent than after pancreaticoduodenectomy; 4) when an invasive adenocarcinoma is suspected in cases of IMPT, partial pancreatectomy appears to be a more acceptable treatment option in view of the high recurrence rates; and 5) in light of the possibility of diagnostic errors, TP should not be performed without preoperative histology.


Back to 2006 Program and Abstracts


Society for Surgery of the Alimentary Tract

Facebook Twitter YouTube

Email SSAT Email SSAT
500 Cummings Center, Suite 4400, Beverly, MA 01915 500 Cummings Center
Suite 4400
Beverly, MA 01915
+1 978-927-8330 +1 978-927-8330
+1 978-524-0498 +1 978-524-0498
Links
About
Membership
Publications
Newsletters
Annual Meeting
Join SSAT
Job Board
Make a Pledge
Event Calendar
Awards